# Natera, Inc.: financial statements, quarterly

NTRA · Nasdaq · CIK 1604821 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ntra.md) · [Financials](/companies/ntra/financials.md) · [Filings](/companies/ntra/filings.md) · [Insiders](/companies/ntra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ntra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [268](/filings/0001558370-24-015325.md) | [311 d](/filings/0001104659-26-020881.md) | [368](/filings/0001558370-25-007036.md) | [413](/filings/0001558370-25-010829.md) | [440](/filings/0001104659-25-107976.md) | [476 d](/filings/0001104659-26-020881.md) | [502](/filings/0001628280-26-032478.md) | [547](/filings/0001628280-26-054525.md) | [592](/filings/0001104659-25-107976.md) | [665 d](/filings/0001104659-26-020881.md) | [697](/filings/0001628280-26-032478.md) | [753](/filings/0001628280-26-054525.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [77.2](/filings/0001558370-24-015325.md) | [83.0 d](/filings/0001104659-26-020881.md) | [88.6](/filings/0001558370-25-007036.md) | [89.1](/filings/0001558370-25-010829.md) | [96.9](/filings/0001104659-25-107976.md) | [129 d](/filings/0001104659-26-020881.md) | [129](/filings/0001628280-26-032478.md) | [146](/filings/0001628280-26-054525.md) | [173](/filings/0001104659-25-107976.md) | [175 d](/filings/0001104659-26-020881.md) | [211](/filings/0001628280-26-032478.md) | [228](/filings/0001628280-26-054525.md) |
| Selling, general and administrative | $m | [155](/filings/0001558370-24-015325.md) | [161 d](/filings/0001104659-26-020881.md) | [194](/filings/0001558370-25-007036.md) | [198](/filings/0001558370-25-010829.md) | [214](/filings/0001104659-25-107976.md) | [235 d](/filings/0001104659-26-020881.md) | [267](/filings/0001628280-26-032478.md) | [311](/filings/0001628280-26-054525.md) | [309](/filings/0001104659-25-107976.md) | [291 d](/filings/0001104659-26-020881.md) | [328](/filings/0001628280-26-032478.md) | [327](/filings/0001628280-26-054525.md) |
| Operating income | $m | [(111)](/filings/0001558370-24-015325.md) | [(84.5) d](/filings/0001104659-26-020881.md) | [(74.3)](/filings/0001558370-25-007036.md) | [(43.9)](/filings/0001558370-25-010829.md) | [(39.3)](/filings/0001104659-25-107976.md) | [(64.7) d](/filings/0001104659-26-020881.md) | [(79.2)](/filings/0001628280-26-032478.md) | [(110)](/filings/0001628280-26-054525.md) | [(97.6)](/filings/0001104659-25-107976.md) | [(22.8) d](/filings/0001104659-26-020881.md) | [(93.5)](/filings/0001628280-26-032478.md) | [(75.8)](/filings/0001628280-26-054525.md) |
| Interest expense | $m | [3.3](/filings/0001558370-24-015325.md) | [3.1 d](/filings/0001104659-26-020881.md) | [3.1](/filings/0001558370-25-007036.md) | [3.1](/filings/0001558370-25-010829.md) | [3.1](/filings/0001104659-25-107976.md) | [1.3 d](/filings/0001104659-26-020881.md) | [1.0](/filings/0001558370-25-007036.md) | [1.0](/filings/0001558370-25-010829.md) | [1.0](/filings/0001104659-25-107976.md) | [1.0 d](/filings/0001104659-26-020881.md) | [0.9](/filings/0001628280-26-032478.md) | [0.9](/filings/0001628280-26-054525.md) |
| Income tax | $m | [0.2](/filings/0001558370-24-015325.md) | [0.2 d](/filings/0001104659-26-020881.md) | [0.4](/filings/0001558370-25-007036.md) | [0.9](/filings/0001558370-25-010829.md) | [0.7](/filings/0001104659-25-107976.md) | [(1.4) d](/filings/0001104659-26-020881.md) | [0.2](/filings/0001628280-26-032478.md) | [0.3](/filings/0001628280-26-054525.md) | [0.2](/filings/0001104659-25-107976.md) | [(60.6) d](/filings/0001104659-26-020881.md) | [0.3](/filings/0001628280-26-032478.md) | [(0.3)](/filings/0001628280-26-054525.md) |
| Net income | $m | [(109)](/filings/0001558370-24-015325.md) | [(78.0) d](/filings/0001104659-26-020881.md) | [(67.6)](/filings/0001558370-25-007036.md) | [(37.5)](/filings/0001558370-25-010829.md) | [(31.6)](/filings/0001104659-25-107976.md) | [(53.8) d](/filings/0001104659-26-020881.md) | [(66.9)](/filings/0001628280-26-032478.md) | [(101)](/filings/0001628280-26-054525.md) | [(87.5)](/filings/0001104659-25-107976.md) | [47.3 d](/filings/0001104659-26-020881.md) | [(85.1)](/filings/0001628280-26-032478.md) | [(67.0)](/filings/0001628280-26-054525.md) |
| Diluted EPS | $ per share | [(0.95)](/filings/0001558370-24-015325.md) | not reported | [(0.56)](/filings/0001558370-25-007036.md) | [(0.30)](/filings/0001558370-25-010829.md) | [(0.26)](/filings/0001104659-25-107976.md) | not reported | [(0.50)](/filings/0001628280-26-032478.md) | [(0.74)](/filings/0001628280-26-054525.md) | [(0.64)](/filings/0001104659-25-107976.md) | not reported | [(0.60)](/filings/0001628280-26-032478.md) | [(0.47)](/filings/0001628280-26-054525.md) |
| Basic EPS | $ per share | [(0.95)](/filings/0001558370-24-015325.md) | not reported | [(0.56)](/filings/0001558370-25-007036.md) | [(0.30)](/filings/0001558370-25-010829.md) | [(0.26)](/filings/0001104659-25-107976.md) | not reported | [(0.50)](/filings/0001628280-26-032478.md) | [(0.74)](/filings/0001628280-26-054525.md) | [(0.64)](/filings/0001104659-25-107976.md) | not reported | [(0.60)](/filings/0001628280-26-032478.md) | [(0.47)](/filings/0001628280-26-054525.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [1,267](/filings/0001558370-23-018379.md) | [1,259](/filings/0001558370-25-001869.md) | [1,261](/filings/0001558370-24-007686.md) | [1,302](/filings/0001558370-24-011666.md) | [1,323](/filings/0001558370-24-015325.md) | [1,376](/filings/0001104659-26-020881.md) | [1,416](/filings/0001558370-25-007036.md) | [1,432](/filings/0001558370-25-010829.md) | [1,447](/filings/0001104659-25-107976.md) | [1,497](/filings/0001628280-26-054525.md) | [1,652](/filings/0001628280-26-032478.md) | [1,659](/filings/0001628280-26-054525.md) |
| Total assets | $m | [1,447](/filings/0001558370-23-018379.md) | [1,442](/filings/0001558370-25-001869.md) | [1,468](/filings/0001558370-24-007686.md) | [1,517](/filings/0001558370-24-011666.md) | [1,591](/filings/0001558370-24-015325.md) | [1,661](/filings/0001104659-26-020881.md) | [1,732](/filings/0001558370-25-007036.md) | [1,757](/filings/0001558370-25-010829.md) | [1,821](/filings/0001104659-25-107976.md) | [2,398](/filings/0001628280-26-054525.md) | [2,614](/filings/0001628280-26-032478.md) | [2,657](/filings/0001628280-26-054525.md) |
| Current liabilities | $m | [290](/filings/0001558370-23-018379.md) | [307](/filings/0001558370-25-001869.md) | [306](/filings/0001558370-24-007686.md) | [315](/filings/0001558370-24-011666.md) | [301](/filings/0001558370-24-015325.md) | [344](/filings/0001104659-26-020881.md) | [366](/filings/0001558370-25-007036.md) | [385](/filings/0001558370-25-010829.md) | [442](/filings/0001104659-25-107976.md) | [441](/filings/0001628280-26-054525.md) | [558](/filings/0001628280-26-032478.md) | [553](/filings/0001628280-26-054525.md) |
| Total liabilities | $m | [662](/filings/0001558370-23-018379.md) | [676](/filings/0001558370-25-001869.md) | [674](/filings/0001558370-24-007686.md) | [680](/filings/0001558370-24-011666.md) | [712](/filings/0001558370-24-015325.md) | [465](/filings/0001104659-26-020881.md) | [493](/filings/0001558370-25-007036.md) | [511](/filings/0001558370-25-010829.md) | [569](/filings/0001104659-25-107976.md) | [686](/filings/0001628280-26-054525.md) | [840](/filings/0001628280-26-032478.md) | [836](/filings/0001628280-26-054525.md) |
| Long-term debt | $m | not reported | [283](/filings/0001558370-25-001869.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [80.4](/filings/0001558370-23-018379.md) | [80.4](/filings/0001558370-25-001869.md) | [80.4](/filings/0001558370-24-007686.md) | [80.4](/filings/0001558370-24-011666.md) | [80.5](/filings/0001558370-24-015325.md) | [80.4](/filings/0001104659-26-020881.md) | [80.3](/filings/0001558370-25-007036.md) | [80.3](/filings/0001558370-25-010829.md) | [80.3](/filings/0001104659-25-107976.md) | [80.3](/filings/0001628280-26-054525.md) | [80.3](/filings/0001628280-26-032478.md) | [80.3](/filings/0001628280-26-054525.md) |
| Shareholders' equity | $m | [785](/filings/0001558370-24-015325.md) | [765](/filings/0001104659-26-020881.md) | [794](/filings/0001558370-25-010829.md) | [837](/filings/0001104659-25-107976.md) | [879](/filings/0001104659-25-107976.md) | [1,195](/filings/0001628280-26-054525.md) | [1,240](/filings/0001628280-26-054525.md) | [1,246](/filings/0001628280-26-054525.md) | [1,252](/filings/0001104659-25-107976.md) | [1,712](/filings/0001628280-26-054525.md) | [1,774](/filings/0001628280-26-054525.md) | [1,821](/filings/0001628280-26-054525.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(29.7) d](/filings/0001558370-24-015325.md) | [(57.6) d](/filings/0001104659-26-020881.md) | [27.0](/filings/0001558370-25-007036.md) | [4.0 d](/filings/0001558370-25-010829.md) | [51.8 d](/filings/0001104659-25-107976.md) | [52.9 d](/filings/0001104659-26-020881.md) | [44.5](/filings/0001628280-26-032478.md) | [37.6 d](/filings/0001628280-26-054525.md) | [59.4 d](/filings/0001104659-25-107976.md) | [73.9 d](/filings/0001104659-26-020881.md) | [40.2](/filings/0001628280-26-032478.md) | [54.8 d](/filings/0001628280-26-054525.md) |
| Capital expenditure | $m | [9.0 d](/filings/0001558370-24-015325.md) | [10.1 d](/filings/0001104659-26-020881.md) | [20.3](/filings/0001558370-25-007036.md) | [11.7 d](/filings/0001558370-25-010829.md) | [16.3 d](/filings/0001104659-25-107976.md) | [18.1 d](/filings/0001104659-26-020881.md) | [21.8](/filings/0001628280-26-032478.md) | [25.9 d](/filings/0001628280-26-054525.md) | [22.4 d](/filings/0001104659-25-107976.md) | [36.1 d](/filings/0001104659-26-020881.md) | [22.1](/filings/0001628280-26-032478.md) | [63.4 d](/filings/0001628280-26-054525.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [97.1](/filings/0001558370-23-018379.md) | [112](/filings/0001558370-24-007686.md) | [114](/filings/0001558370-24-011666.md) | [115](/filings/0001558370-24-015325.md) | [121](/filings/0001558370-25-007036.md) | [123](/filings/0001558370-25-010829.md) | [124](/filings/0001104659-25-107976.md) | [135](/filings/0001628280-26-032478.md) | [136](/filings/0001628280-26-054525.md) | [137](/filings/0001104659-25-107976.md) | [142](/filings/0001628280-26-032478.md) | [143](/filings/0001628280-26-054525.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 144,144,170 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001628280-26-054525.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.